Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Ellen P, Hart"'
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-11 (2021)
Abstract Background In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF
Externí odkaz:
https://doaj.org/article/a7689931f0644552b7feafa5d357d2b7
Autor:
Charlotte Bakker, Tim Tasker, Jan Liptrot, Ellen P. Hart, Erica S. Klaassen, Robert Jan Doll, Giles A. Brown, Alastair Brown, Miles Congreve, Malcolm Weir, Fiona H. Marshall, David M. Cross, Geert Jan Groeneveld, Pradeep J. Nathan
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-19 (2021)
Abstract Background The cholinergic system and M1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M1 receptor partial agonist HTL0018318 is under development for the symptomatic treatment of Demen
Externí odkaz:
https://doaj.org/article/8f25b2ca13ee46c9988b118de2ad5f58
Autor:
Charlotte Bakker, Jasper van derAart, Ellen P. Hart, Erica S. Klaassen, Kirsten R. Bergmann, Michiel J. vanEsdonk, Denis G. Kay, Geert Jan Groeneveld
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 6, Iss 1, Pp n/a-n/a (2020)
Abstract Introduction Gln‐1062 (MEMOGAIN) is an intranasally administered lipophilic prodrug of galantamine. Based on high brain‐to‐blood concentrations observed in pre‐clinical studies, Gln‐1062 is expected to have superior cognitive effic
Externí odkaz:
https://doaj.org/article/a354bb9655804faf9b6e8de71a99a031
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-11 (2021)
Alzheimer's Research and Therapy
ISSUE=13;TITLE=Alzheimer's Research and Therapy
Alzheimer's Research & Therapy
Alzheimer's Research and Therapy
ISSUE=13;TITLE=Alzheimer's Research and Therapy
Alzheimer's Research & Therapy
Background In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF) amyloid
Autor:
Wadim M. I. de Boon, Emilie M. J. van Brummelen, Robert Doll, Dimitrios Ziagkos, Petteri Kolehmainen, Geert Jan Groeneveld, Teppo Huttunen, Ellen P. Hart
Publikováno v:
Journal of Clinical Movement Disorders, Vol 7, Iss 1, Pp 1-11 (2020)
Journal of Clinical Movement Disorders
Journal of Clinical Movement Disorders
Background To quantify pharmacological effects on tremor in patients with essential tremor (ET) or Parkinson’s Disease (PD), laboratory-grade accelerometers have previously been used. Over the last years, consumer products such as smartphones and s
Autor:
Tim Tasker, Charlotte Bakker, Giles A. Brown, Alastair J. H. Brown, Geert Jan Groeneveld, Fiona H. Marshall, Erica S. Klaassen, Jasper Stevens, Ellen P. Hart, Miles Congreve, Samantha Prins, Jan Liptrot, Malcolm Peter Weir, David M. Cross, Pradeep J. Nathan
Publikováno v:
British Journal of Clinical Pharmacology, 87(11), 4439-4449. Wiley
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 87(11), 4439-4449. WILEY
British Journal of Clinical Pharmacology
British Journal of Clinical Pharmacology, 87(11), 4439-4449. WILEY
Aims HTL0009936 is a selective M-1 muscarinic receptor agonist in development for cognitive dysfunction in Alzheimer's disease. Safety, tolerability and pharmacokinetics and exploratory pharmacodynamic effects of HTL0009936 administered by continuous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1cfc7d33e6c4530c79bb4ddfa7c803
https://hdl.handle.net/1887/3278297
https://hdl.handle.net/1887/3278297
Autor:
Geert Jan Groeneveld, Tim Tasker, Malcolm Peter Weir, Jan Liptrot, Giles A. Brown, Pradeep J. Nathan, Charlotte Bakker, Ellen P. Hart, Miles Congreve, Robert Doll, Alastair J. H. Brown, Fiona H. Marshall, Erica S. Klaassen, David M. Cross
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-19 (2021)
Alzheimer's Research and Therapy, 13(1). BMC
Alzheimer's Research and Therapy, 13(1). BMC
Funder: Sosei Heptares
BACKGROUND: The cholinergic system and M1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M1 receptor partial agonist HTL0018318 is under development for the symptomati
BACKGROUND: The cholinergic system and M1 receptor remain an important target for symptomatic treatment of cognitive dysfunction. The selective M1 receptor partial agonist HTL0018318 is under development for the symptomati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13554a98510e34c88b67694e84accad4
Autor:
Simon-Shlomo Poil, Huibert D. Mansvelder, Samantha Prins, Klaus Linkenkaer-Hansen, Geert Jan Groeneveld, Ellen P. Hart, Sonja Simpraga
Publikováno v:
Simpraga, S, Mansvelder, H D, Groeneveld, G J, Prins, S, Hart, E P, Poil, S S & Linkenkaer-Hansen, K 2018, ' An EEG nicotinic acetylcholine index to assess the efficacy of pro-cognitive compounds ', Clinical Neurophysiology, vol. 129, no. 11, pp. 2325-2332 . https://doi.org/10.1016/j.clinph.2018.08.014
Clinical Neurophysiology, 129(11), 2325-2332. International Federation of Clinical Neurophysiology
Clinical Neurophysiology, 129(11), 2325-2332. International Federation of Clinical Neurophysiology
Objectives Cognitive impairment models are used in clinical studies aimed at proving pharmacology of drugs being developed for Alzheimer’s disease and other cognitive disorders. Due to rising interest in nicotinic agonists, we aimed to establish a
Autor:
Raymund A.C. Roos, Ellen P. Hart, Egbert A. J. F. Lakke, Emma M. Coppen, Jeroen van der Grond
Publikováno v:
Behavioural Brain Research, 351, 63-74
The processing of visual stimuli from retina to higher cortical areas has been extensively studied in the human brain. In Huntington's disease (HD), an inherited neurodegenerative disorder, it is suggested that visual processing deficits are present
Autor:
Thalia F. van der Doef, Jan Liptrot, Pradeep J. Nathan, Geert Jan Groeneveld, Fiona H. Marshall, Giles A. Brown, Malcolm Peter Weir, David M. Cross, Ellen P. Hart, Miles Congreve, Erica S. Klaassen, Charlotte Bakker, Samantha Prins, Alastair J. H. Brown, Tim Tasker
Publikováno v:
British Journal of Clinical Pharmacology, 87(7), 2945-2955. WILEY
Aims HTL0018318 is a selective M1 receptor partial agonist currently under development for the symptomatic treatment of cognitive and behavioural symptoms in Alzheimer's disease (AD) and other dementias. We investigated safety, tolerability, pharmaco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55ad396ea5399fd0002c8983f5f7c00d
https://doi.org/10.1111/bcp.14710
https://doi.org/10.1111/bcp.14710